Citius Pharmaceuticals (CTXR) Competitors $1.17 +0.03 (+2.63%) Closing price 09/16/2025 04:00 PM EasternExtended Trading$1.18 +0.01 (+0.85%) As of 09/16/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTXR vs. ELUT, SLGL, PMVP, UNCY, ASRT, IGMS, IRD, IMUX, BYSI, and IZTCShould you be buying Citius Pharmaceuticals stock or one of its competitors? The main competitors of Citius Pharmaceuticals include Elutia (ELUT), Sol-Gel Technologies (SLGL), PMV Pharmaceuticals (PMVP), Unicycive Therapeutics (UNCY), Assertio (ASRT), IGM Biosciences (IGMS), Opus Genetics (IRD), Immunic (IMUX), BeyondSpring (BYSI), and Invizyne Technologies (IZTC). These companies are all part of the "pharmaceutical products" industry. Citius Pharmaceuticals vs. Its Competitors Elutia Sol-Gel Technologies PMV Pharmaceuticals Unicycive Therapeutics Assertio IGM Biosciences Opus Genetics Immunic BeyondSpring Invizyne Technologies Elutia (NASDAQ:ELUT) and Citius Pharmaceuticals (NASDAQ:CTXR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership. Do institutionals & insiders hold more shares of ELUT or CTXR? 74.0% of Elutia shares are owned by institutional investors. Comparatively, 16.9% of Citius Pharmaceuticals shares are owned by institutional investors. 27.6% of Elutia shares are owned by company insiders. Comparatively, 10.7% of Citius Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the media prefer ELUT or CTXR? In the previous week, Elutia had 5 more articles in the media than Citius Pharmaceuticals. MarketBeat recorded 9 mentions for Elutia and 4 mentions for Citius Pharmaceuticals. Elutia's average media sentiment score of 0.24 beat Citius Pharmaceuticals' score of 0.18 indicating that Elutia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elutia 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Citius Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer ELUT or CTXR? Elutia currently has a consensus price target of $7.00, indicating a potential upside of 493.22%. Citius Pharmaceuticals has a consensus price target of $53.00, indicating a potential upside of 4,429.91%. Given Citius Pharmaceuticals' higher probable upside, analysts clearly believe Citius Pharmaceuticals is more favorable than Elutia.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elutia 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Citius Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has higher valuation & earnings, ELUT or CTXR? Citius Pharmaceuticals has lower revenue, but higher earnings than Elutia. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElutia$24.38M2.05-$53.95M-$1.06-1.11Citius PharmaceuticalsN/AN/A-$39.14MN/AN/A Is ELUT or CTXR more profitable? Citius Pharmaceuticals has a net margin of 0.00% compared to Elutia's net margin of -90.01%. Elutia's return on equity of 0.00% beat Citius Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Elutia-90.01% N/A -54.08% Citius Pharmaceuticals N/A -60.03%-33.83% Which has more risk and volatility, ELUT or CTXR? Elutia has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500. Comparatively, Citius Pharmaceuticals has a beta of 1.35, indicating that its stock price is 35% more volatile than the S&P 500. SummaryElutia beats Citius Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Get Citius Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CTXR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTXR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTXR vs. The Competition Export to ExcelMetricCitius PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.39M$2.55B$5.73B$10.31BDividend YieldN/A60.31%5.90%4.63%P/E RatioN/A23.4976.0226.51Price / SalesN/A672.77533.19123.58Price / CashN/A169.4937.1760.46Price / Book0.115.3313.806.29Net Income-$39.14M$32.95M$3.28B$270.51M7 Day Performance-3.31%0.10%0.82%1.95%1 Month Performance-12.03%3.91%4.62%6.33%1 Year Performance-90.66%-3.91%82.65%25.62% Citius Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTXRCitius Pharmaceuticals2.3618 of 5 stars$1.17+2.6%$53.00+4,429.9%-90.7%$19.39MN/A0.0020Short Interest ↑ELUTElutia3.081 of 5 stars$1.88flat$8.00+325.5%-71.4%$79.70M$24.38M0.00180News CoverageGap DownSLGLSol-Gel Technologies0.7187 of 5 stars$27.55-1.5%N/A+273.4%$77.89M$11.54M-22.4050Short Interest ↑PMVPPMV Pharmaceuticals2.8708 of 5 stars$1.40-4.1%$5.50+292.9%-20.0%$77.37MN/A-0.8950UNCYUnicycive Therapeutics2.2996 of 5 stars$4.37+0.2%$60.00+1,273.0%+6.3%$77M$680K-1.069Analyst ForecastASRTAssertio1.7294 of 5 stars$0.80+0.9%$2.38+195.1%-32.3%$76.78M$124.96M0.0020News CoverageIGMSIGM Biosciences2.7418 of 5 stars$1.27flat$4.89+285.0%N/A$76.57M$145.05M-1.41190IRDOpus Genetics2.4095 of 5 stars$1.40+10.2%$7.33+423.8%N/A$76.08M$10.99M0.0014Gap UpHigh Trading VolumeIMUXImmunic1.8124 of 5 stars$0.83+9.1%$7.50+803.6%-49.1%$75.07MN/A0.0070Gap UpBYSIBeyondSpringN/A$1.90+2.2%N/A-12.8%$75.02M$1.75M0.0080News CoverageGap DownIZTCInvizyne TechnologiesN/A$11.96+13.1%N/AN/A$74.77MN/A0.0029Gap Up Related Companies and Tools Related Companies ELUT Competitors SLGL Competitors PMVP Competitors UNCY Competitors ASRT Competitors IGMS Competitors IRD Competitors IMUX Competitors BYSI Competitors IZTC Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTXR) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Citius Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Citius Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTXR Stock Alerts